Introduction: Prostate is one of the most commonly affected organ in males with increasing age. Prostatic lesions like Benign Prostatic Hyperplasia, Prostatic Adenocarcinoma account for significant morbidity and mortality. Though the diagnosis of malignant tumours of prostate can be made with morphological features, it is sometimes very difficult to reach a definitive diagnosis by routine histopathological examination alone.Therefore, the Immunohistochemistry is very useful in distinguishing the prostate cancer from benign lesions, especially in equivocal cases. Based on this aim of our study is to study the spectrum of various Prostatic lesions and also to study the expression of Immunohistochemical markers P63 and AMACR in benign and malignant cases. Materials and methods:The present study is a prospective study of prostate biopsies of 115 clinically suspected cases of prostatic lesions who were reported in the Department of Urology, in our institution during the period from December 2020 - June 2022. All these 115 biopsies were subjected to histopathological examination and categorized into benign and malignant lesions. Histological grading was done using Gleason’s scoring system for all the prostatic carcinoma cases. Immunohistochemical examination was done using the immunostains P63 and AMACR in selected cases. Results: In our study, p63 has sensitivity of 100%, specificity of 100% and diagnostic accuracy of 100% where as AMACR has sensitivity of 100%, specificity of 86.67% and diagnostic accuracy of 93.33%. P value of less than 0.05% was considered significant. Association of type of lesion with P63 and AMACR was significant with p value < 0.001. Conclusion:The histopathological examination is still the gold standard modality for the diagnosis of prostatic lesions, Immunohistochemistry with p63 and AMACR in the assessment of prostatic lesions, is of immense additional value in further confirming the histomorphologically diagnosed prostatic benign and malignant cases.